ACHV
NASDAQAchieve Life Sciences Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News · 26 weeks51-47%
2025-12-142026-06-07
Mix3790d
- SEC Filings13(35%)
- Insider11(30%)
- Other6(16%)
- Earnings4(11%)
- Leadership2(5%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Waldman Reid Alexander4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Farrow Jeffrey S4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERNew insider Waldman Reid Alexander claimed no ownership of stock in the company (SEC Form 3)3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERNew insider Farrow Jeffrey S claimed no ownership of stock in the company (SEC Form 3)3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- SECAchieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- PRAchieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of DirectorsSEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat
- SECSEC Form PRE 14A filed by Achieve Life Sciences Inc.PRE 14A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- SECSEC Form EFFECT filed by Achieve Life Sciences Inc.EFFECT - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- PRAchieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline TreatmentORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure Nausea — a common barrier to treatment adherence with smoking cessation therapies — was reported in only 2.5% of participants over 52 weeks of continuous exposure¹ SEATTLE and VANCOUVER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today
- INSIDERSEC Form 4 filed by Director Martin Christopher Nathan4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERNew insider Martin Christopher Nathan claimed no ownership of stock in the company (SEC Form 3)3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- SECSEC Form S-3 filed by Achieve Life Sciences Inc.S-3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- SECSEC Form S-8 filed by Achieve Life Sciences Inc.S-8 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- SECSEC Form 10-Q filed by Achieve Life Sciences Inc.10-Q - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- SECAchieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Results of Operations and Financial Condition8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- PRAchieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona PharmaSEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced three senior leadership appointments. Christopher Martin has joined the Company's Board of Directors. Mark Zappia has joined as Senior Vice President, Commercial, where he will spearhead the Company's commercial function. Jim Willis has joined as Vice President of Sales and Sales Enablement, where he will lead the field force. Mr. Martin most recently served as Chief Commercia
- PRAchieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdatesClosed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based Manufacturing Transition & Partnership Conference Call Scheduled for 8:30 AM EDT Today, May 12, 2026 SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the first quarter of 2026 and provided corporate highlights
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Achieve Life Sciences Inc.SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
- PRAchieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its first quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q26 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or +1 201-689-7817 (International) and referencing conference ID 13759781. A webcast replay will be avail
- SECAmendment: SEC Form 10-K/A filed by Achieve Life Sciences Inc.10-K/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- INSIDERNew insider Royston Aaron claimed no ownership of stock in the company (SEC Form 3)3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERNew insider Tpg Gp A, Llc claimed ownership of 6,877,580 shares (SEC Form 3)3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERNew insider Iancovici Lucian claimed no ownership of stock in the company (SEC Form 3)3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Goldberg Andrew D.4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 3 filed by new insider Goldberg Andrew D.3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
ACHV FAQ
6 questionsWhat does Achieve Life Sciences Inc. do?
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.Where does ACHV stock trade?
Achieve Life Sciences Inc. (ACHV) is listed on NASDAQ.What sector and industry is ACHV in?
Achieve Life Sciences Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about ACHV?
Achieve Life Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $1300.00 price target on 2026-04-21. Recent price targets range from $1200.00 to $2500.00.What companies are similar to ACHV?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare ACHV side-by-side with any of them on Quantisnow.How can I track ACHV on Quantisnow?
Quantisnow aggregates Achieve Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACHV to receive live email and push alerts on every new disclosure.